Pure Global AI
NCT06236282Completed

ArtiSential® for Rectal Cancer Surgery

Safety and Efficacy of Flexible Articulated Instrument (ArtiSential®) in Laparoscopic Surgery for Rectal Cancer
Seoul National University HospitalClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Rectal Cancer
Drug/Device/Intervention
ArtiSential®
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Seoul National University Hospital
Location
Seoul, South Korea
Timeline & enrollment
Phase
N/A
Start date
May 01, 2012
End date
Mar 31, 2023
Enrollment
93 participants
Primary outcome

Operation time

Summary

This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer
 surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic
 low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a
 single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group,
 based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and
 resection margin status did not differ between the groups. ArtiSential® reduced operative
 time without impairing surgical quality or oncologic outcomes.

ICD-10 classifications
Malignant neoplasm of rectumCarcinoma in situ: RectumBenign neoplasm: RectumSecondary malignant neoplasm of large intestine and rectumCarcinoma in situ: Rectosigmoid junction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06236282
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06236282 through Pure Global AI's free database. This phase not specified trial is sponsored by Seoul National University Hospital and is currently Completed. The study focuses on Rectal Cancer. Target enrollment is 93 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.